{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:37:45Z","timestamp":1777934265581,"version":"3.51.4"},"reference-count":16,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2016,9,8]],"date-time":"2016-09-08T00:00:00Z","timestamp":1473292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:p>The programmed-death-1 inhibitors selectively block programmed-death-1 interaction with its receptor, which restores active T-cell response directed at tumor cells, inducing an anti-tumor effect. This nonspecific activation of the immune system can also lead to a wide spectrum of side effects. Nivolumab has been used effectively to prolong survival in patients with metastatic melanoma and is recommended as a category 1 agent for systemic therapy in metastatic or unresectable melanoma per the National Comprehensive Cancer Network guidelines. We present a case of a 64-year-old woman who began nivolumab therapy for metastatic melanoma. After six doses of nivolumab therapy, the patient experienced generalized hypopigmentation on her face, chest, back, arms, and lower extremities. Although vitiligo has been reported in as many as 10.7% of patients undergoing nivolumab therapy in some clinical trials, we believe this is the first case to describe the progression of nivolumab-induced vitiligo in a metastatic melanoma patient. This case provides significant insight into the onset, symptoms, development, and treatment options for patients experiencing vitiligo as a result of nivolumab therapy.<\/jats:p>","DOI":"10.1177\/1078155216667636","type":"journal-article","created":{"date-parts":[[2016,9,8]],"date-time":"2016-09-08T21:29:05Z","timestamp":1473370145000},"page":"629-634","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Nivolumab-induced vitiligo in a metastatic melanoma patient: A case report"],"prefix":"10.1177","volume":"23","author":[{"given":"Lindsay A","family":"Edmondson","sequence":"first","affiliation":[{"name":"Seton Healthcare Family, Austin, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leticia V","family":"Smith","sequence":"additional","affiliation":[{"name":"Seton Healthcare Family, Austin, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alka","family":"Mallik","sequence":"additional","affiliation":[{"name":"Seton Healthcare Family, Austin, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2016,9,8]]},"reference":[{"key":"bibr1-1078155216667636","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology.\n                      Melanoma\n                      , v2.2016, http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/melanoma.pdf (2015, accessed 30 August 2016)."},{"key":"bibr2-1078155216667636","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"bibr3-1078155216667636","unstructured":"OPDIVO [package insert]. Princeton, NJ: Bristol-Myers Squibb Company, 2015."},{"key":"bibr4-1078155216667636","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.07.033"},{"key":"bibr5-1078155216667636","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"bibr6-1078155216667636","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60763-7"},{"key":"bibr7-1078155216667636","unstructured":"NCI common terminology criteria for adverse events\n                      (CTCAE) v.4 data files. Bethesda, MD: National Cancer Institute."},{"key":"bibr8-1078155216667636","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.0105"},{"key":"bibr9-1078155216667636","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr10-1078155216667636","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3061"},{"key":"bibr11-1078155216667636","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"bibr12-1078155216667636","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"bibr13-1078155216667636","unstructured":"Lexi-Comp Online\u2122 and Lexi-Drugs Online\u2122. Hudson, OH: Lexi-Comp, Inc., 2014."},{"key":"bibr14-1078155216667636","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2008.06755.x"},{"key":"bibr15-1078155216667636","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp325"},{"key":"bibr16-1078155216667636","doi-asserted-by":"crossref","unstructured":"Taieb A, Alomar A, Bohm M, et al. Vitiligo European Task Force (VETF), and the European Academy of Dermatology and Venereology (EADV), and the Union Europ\u00e9enne des M\u00e9decins Sp\u00e9cialistes (UEMS). Guidelines for the management of vitiligo: the European Dermatology Forum consensus.\n                      Br J Dermatol\n                      2013; 168: 5\u201319.","DOI":"10.1111\/j.1365-2133.2012.11197.x"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155216667636","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155216667636","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155216667636","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:16:56Z","timestamp":1777688216000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155216667636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,8]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1177\/1078155216667636"],"URL":"https:\/\/doi.org\/10.1177\/1078155216667636","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,8]]}}}